Citius Oncology, Inc. 8-K Report: Key Insights & Stock Updates (Jan 6, 2025)
Here's the extracted key information and insights from the provided section of the financial report:
- Entity Information:
- Name: Citius Oncology, Inc.
- CIK: 0001851484
- State of Incorporation: Delaware (DE)
- SEC File Number: 001-41534
- EIN: 99-4362660
- Address: 11 Commerce Drive, 1st Floor, Cranford, NJ 07016
- Phone: 908-967-6677
- Filing Details:
- Form Type: 8-K (Current Report)
- Filing Date: January 6, 2025
- Financial Metrics:
- Measurement Unit:
- Currency: USD (U.S. Dollars)
- Shares: Common Stock
- Unit Measurement Context:
- The financial data is provided in both USD and shares, indicating a potential discussion of stock performance, share issuance, or other equity-related metrics.
- Stock Information:
- Common Stock Ticker Symbol: CTOR
- Exchange: NASDAQ
- Time Frame:
- The report pertains to a specific date, January 6, 2025, suggesting it may include significant events or disclosures that occurred on that date.
Insights:
- The filing is an 8-K, which typically reports major events that shareholders should be aware of, indicating that something significant occurred on or prior to January 6, 2025.
- The presence of both financial and stock information suggests that the report may cover aspects such as changes in stock structure, financial performance updates, or other critical corporate actions.
- As a company listed on NASDAQ, Citius Oncology, Inc. is subject to stringent reporting requirements, which can provide a level of assurance regarding the reliability of the information presented.
This information is crucial for investors and analysts looking to evaluate Citius Oncology's current standing and potential future performance.
